W5 FSD Documentary on CTV (Pharma Sutra)

December 3, 2008

female viagraW-Five (W5) is an investigative journalism show on Canada’s CTV network (think “60 Minutes”, “20/20” “Dateline NBC” etc). And this coming Saturday, December 6 they are either showing or talking about a documentary called “Pharma Sutra” that talks about three treatments in development for FSD (Female Sexual Dysfunction), or FSAD (Female Sexual Arousal Disorder).

The treatments are a pill (?), a patch – which is likely the testosterone patch which didn’t get approved by the FDA but is available by prescription in the UK, and a nasal spray – which is certainly either going to be Bremelanotide or its successor from the same company, PL-6983 (depending on how uptodate this documentary is).

I’ll post more when the documentary airs, but until then you can read a bit about that “Pharma Sutra” documentary here, or about Bremelanotide (called the ‘female viagra’) or Pl-6983 or Palatin Technologies, who is developing PL-6983, after their attempt to get FDA approval of Bremelanotide was shot down.

Let’s hope the documentary has some good news! :-)





PL-6983 – is it a true aphrodisiac?

September 4, 2008

This is my new blog about a product / treatment I just read about. It’s called PL-6983 and is in development to treat female sexual arousal disorder (FSAD) and eventually erectile dysfunction (ED) as well.

The company developing it is Palatin Technologies and PL-6983 is a second attempt at such a drug. Their first attempt was with a drug initially called PT-141 and then formally named ‘Bremelanotide’… much like PL-6983 will eventually be given a real name.

Unfortunately the FDA did not approve Palatin’s application for Bremelanotide to be used as a treatment for ED, citing concerns about high blood pressure in some people who tested it. However it’s been commented here and there that it’s a bit of a double standard when you consider that Viagra WAS approved and it can cause LOW blood pressure in some people.

So Palatin has now moved onto a slightly different compound that apparently causes less instances or less significant blood pressure concerns in the rats (or whatever) that they’ve tested it on.

I intend to use this blog to follow the progress of PL-6983’s clinical trials and it (hopefully) eventual approval by the FDA.

Additional resources include:

Palatin Technologies: the developer of PL-6983 and Bremelanotide

– The Bremelanotide Bulletin: a periodically updated website / newsletter with info about Bremelanotide, PL-6983, and similar treatments in development

PL-6983.com: Obviously a site dedicated to this new treatment. Not much there as of the time of this writing, but likely will once clinical trials begin.


Get every new post delivered to your Inbox.